Surveillance and monitoring studies of antimicrobial resistance in bacteria of human and animal origin and antimicrobial consumption in humans and animals have been conducted in various countries throughout the world. In the veterinary field, in particular, programmes have been installed which target bacteria of zoonotic, foodborne and/or veterinary relevance. Each year, the European Surveillance of Veterinary Antimicrobial Consumption project summarises and evaluates antimicrobial consumption in ambulatory and hospital care in many European countries. In contrast, antimicrobial consumption data in veterinary medicine are available from only a few countries and the type of information that is collected or reported varies. To address this challenge, the European Surveillance of Veterinary Antimicrobial Consumption project was launched by the European Medicines Agency in September 2009 and has just published its first report. This comparison of the different studies for surveillance and monitoring of antimicrobial resistance and antimicrobial consumption in humans and animals shows the need to improve harmonisation.
Introduction
Surveillance and monitoring studies on antimicrobial resistance in bacteria that cause infections in humans and animals, and also in indicator bacteria, are essential when studying changes in the antimicrobial susceptibility patterns of these organisms over time and to identify emerging resistance properties. In this regard, surveillance is defined as the continuous, intensive, targeted and nonrandom collection of data on the incidence, prevalence and spread of antimicrobial-resistant bacteria and antimicrobial resistance genes. Monitoring is defined as the continuous routine measurement and analysis of antimicrobial susceptibility testing information to detect trends (9) . Surveillance and monitoring studies are currently conducted in many countries in both human and veterinary medicine. Since the use of antimicrobial agents is considered a driving force in the development and spread of antimicrobial resistance, studies have also been conducted to determine consumption figures of antimicrobial agents in human and veterinary medicine in various countries.
This review summarises the key features of some of these surveillance and monitoring studies on antimicrobial resistance and antimicrobial consumption, without intending to be exhaustive. Moreover, some basic information is given on the methodologies and interpretive criteria used in these studies. All these data emphasise the need for better harmonisation of such surveillance and monitoring studies (31, 37, 38, 39) .
Surveillance and monitoring of antimicrobial resistance

Methodologies of antimicrobial susceptibility testing in surveillance and monitoring programmes
There is no uniform harmonised methodology of antimicrobial susceptibility testing (AST) among the various surveillance and monitoring programmes in human and veterinary medicine. In general, agar disc diffusion and broth microdilution are the most commonly used methods. However, there is a tendency to give preference to broth microdilution over agar disc diffusion since this is the more robust test method and provides quantitative results. Nevertheless, both are approved AST methods and detailed descriptions of the test conditions have been published by numerous national and international organisations, such as the Clinical and Laboratory Standards Institute (CLSI) (8, 10) , the British Society for Antimicrobial Chemotherapy (2), the Deutsches Institut für Normung e.V. (14) , the Comité de l'Antibiogramme de la Société Française de Microbiologie (11) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) (16) , among others. However, when comparing the AST procedures recommended for different organisms in detail, slight variations occur in the proposed media and supplements, incubation times and conditions, inoculum sizes, etc. Moreover, different clinical breakpoints and/or different epidemiological cut-off values are listed in the various AST documents. For a comparison of data derived from different surveillance or monitoring programmes, it is important to know which AST procedure was followed and which interpretive criteria were used to classify the organisms as susceptible, intermediate and resistant or as wild-type and non-wild-type.
There is also no harmonised set of antimicrobial agents for resistance testing in bacteria in surveillance or monitoring programmes in human or veterinary medicine.
Gram-positive and/or Gram-negative bacteria may be tested for resistance to various sets of antimicrobial agents, while differences may also occur when bacteria from specific disease conditions are tested, e.g. respiratory tract infections versus urinary tract infections versus mastitis. Even when testing the same bacteria for susceptibility to the same antimicrobial agent, there may be striking differences in terms of the test ranges used:
-for the same bacteria in different programmes -for different bacteria in the same programme. Definition of resistance in surveillance and monitoring programmes Schwarz et al. (29, 30) suggested categorising bacterial isolates as 'susceptible to', 'intermediate' or 'resistant to' tested antimicrobials, making the important point that such classification requires approved interpretive criteria. Currently, two different types of interpretive criteria are available: clinical breakpoints and epidemiological cut-off values (6) . The emphasis of a particular study dictates which criteria must be applied. If data are intended to guide a therapeutic approach (i.e. the aim of the study is to determine which antimicrobial agents are most likely to lead to therapeutic success), clinical breakpoints must be applied. Epidemiological cut-off values should be used to describe minimum inhibitory concentration (MIC) distributions of bacteria without clinical context. Clinical breakpoints and epidemiological cut-off values may be very similar or even identical for some bacteria/drug combinations; however, authors need to understand that epidemiological cut-off values are determined by a different approach from that used for clinical breakpoints and do not necessarily take into account the results of clinical efficacy studies or dosing and route of administration of the antimicrobial agents, nor the drug' s pharmacokinetic and pharmacodynamic parameters in the respective animal species. The term 'breakpoint' should be used exclusively for clinical breakpoints and 'susceptible', 'intermediate' and 'resistant' categories should also be reserved for classifications made for the therapeutic application of antimicrobial agents.
When reporting data using epidemiological cut-off values, the term 'resistant' is inappropriate; instead, bacteria should be reported as 'wild type' if the MIC or zone diameter falls within the wild-type range, or 'non-wild type' if the MIC is higher or the zone diameter smaller than the wild-type range. Indeed, Magiorakos et al. (24) , in an international expert proposal for interim standard definitions of acquired resistance, clearly states that a bacterial isolate should only be considered non-susceptible to an antimicrobial agent when it tests resistant, intermediate or non-susceptible using clinical breakpoints as interpretive criteria, not epidemiological cut-offs.
Surveillance and monitoring programmes in human medicine
At any given time, there are numerous antimicrobial resistance (AMR) surveillance and monitoring studies of bacteria. Although the vast majority of these studies evaluate the antimicrobial susceptibility of human pathogens, their goals mirror, in many ways, those of AMR surveillance studies of veterinary pathogens. A large number of AMR surveillance studies, varying in scope and magnitude, have been conducted. Some have focused on a single species of microorganism, a specified time period, a specific geographic region, a single type of infection, or a limited number of antimicrobial agents, while others have been very broad in their coverage of one or more of these aspects (9) . Nevertheless, publications reporting the results of these disparate studies frequently present the data in very similar ways, using a rather limited collection of table or graph formats. Table I gives an overview of four AMR surveillance and monitoring programmes for bacteria of human origin. One of the key differences between human and veterinary AMR surveillance programmes is that human programmes predominantly monitor target pathogens while veterinary programmes, in general, monitor for antimicrobial resistance in foodborne and commensal bacteria. Data interpretation is easier in human AMR surveillance studies than in veterinary AMR surveillance studies. This is primarily because clinical breakpoints specific for the human use of antibiotics against bacteria of human origin have been established by both the CLSI and EUCAST. In the absence of clinical breakpoints, mainly for a number of older antibiotics, there are at present no alternative interpretive criteria, such as epidemiological cut-off values. For interpreting data in veterinary AMR surveillance and monitoring studies, the CLSI document M31-A3 (8) includes the largest collection of approved clinical breakpoints for bacteria of animal origin currently available, a considerable number of which represent veterinary-specific breakpoints. Many of the latter have been approved for specific disease conditions, often caused by particular bacterial species in defined animal host species. As an example, approved clinical breakpoints for enrofloxacin in cattle apply exclusively to bovine respiratory diseases due to Pasteurella multocida, Mannheimia haemolytica and Histophilus somni. The use of these breakpoints for other bovine bacteria and disease conditions, e.g. Staphylococcus aureus from bovine mastitis, is not acceptable (29, 30) . Thus, the scope of application of these veterinary-specific breakpoints is clearly defined and cannot be altered. Besides CLSI-approved clinical breakpoints, EUCAST epidemiological cut-off values are often used (Table II) . Only the SVARM programme follows the recommendations of the Swedish Reference Group for Antibiotics.
Surveillance and monitoring programmes in veterinary medicine
It is clear that the breadth of veterinary AMR surveillance and monitoring programmes is far greater than that of human AMR surveillance and monitoring programmes, since they have to include every host animal species. As with human AMR surveillance and monitoring programmes, the majority of the veterinary programmes are government funded. Apart from the CEESA programmes, all the veterinary AMR surveillance and monitoring programmes are national programmes. Under the umbrella of CEESA, the veterinary pharmaceutical industry conducts four AMR resistance surveillance and monitoring programmes:
-VetPath: examines the antimicrobial susceptibility of major disease-causing bacterial pathogens in food animals -European Antimicrobial Susceptibility Surveillance in Animals (EASSA): examines the antimicrobial susceptibility of foodborne and commensal bacteria in food animals -ComPath: examines the antimicrobial susceptibility of major disease-causing bacterial pathogens in companion animals Longitudinal?
Yes (10) Yes (14) Yes (23) Yes (8) Longitudinal?
Yes (15) Yes (9) Yes (16) Yes (10) Yes (9) Yes (8) 
Antibiotic consumption
Antibiotic consumption in human medicine
The basic unit for consumption of antimicrobial agents in human medicine is the defined daily dose (DDD). According to the definition of the World Health Organization (WHO), DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It should be noted that the number of DDDs for each antimicrobial agent is a technical unit of measurement and not necessarily a measure of good practice (19).
There are numerous studies in various countries which aim to determine the consumption of antimicrobial agents in human medicine, differentiated by their use in hospital care and in ambulatory care (i.e. outpatient care or in the care of a medical practitioner). In Germany, for example, data on antimicrobial consumption in ambulatory care were mainly derived from the databases of the health insurance companies while data on hospital consumption were obtained from two major surveillance projects: were at the higher end (Fig. 3) . It should be noted that approximately 85% to 90% of all prescriptions in ESACparticipating countries are given in ambulatory care.
In all countries included in the ESAC project, penicillins were the most frequently used antimicrobial agents in both ambulatory and hospital care (with amoxicillin as the most prescribed drug in this class). In ambulatory care, the second most frequently used antimicrobial classes were either macrolides-lincosamides-streptogramins (e.g. Greece, Italy, France, Slovakia, Ireland and Austria) or tetracyclines (e.g. Germany, Belgium, the United Kingdom [UK], Finland and Iceland). In hospital care, the second most frequently used antimicrobial agents were either cephalosporins and other beta-lactams (e.g. Finland, Latvia, Russia, Lithuania and Bulgaria), (fluoro-) quinolones (e.g. Italy and France) or macrolideslincosamides-streptogramins (e.g. Ireland).
From these overall consumption figures, a detailed analysis of these prescriptions has identified differences not only according to the specialisation of the prescribing doctor and the age group of the patient, but also due to region and season. Studies in Germany summarised in the GERMAP report 2008 (26) reported that the DDDs per 1,000 inhabitants and day varied between 14.5 and 17.0 in western Germany but between 9.4 and 11.5 in the eastern part. General practitioners prescribed approximately 56% of the antimicrobial agents used in ambulatory care, followed by internists (14%) and paediatricians (9%). The highest prescription rate was seen among children of less than five years of age. Moreover, due to the more frequent occurrence of respiratory tract infections in winter, antimicrobial agents which are particularly active against respiratory tract pathogens (␤-lactams, macrolides and fluoroquinolones) were prescribed more often during the winter months. In contrast, antimicrobial agents that are mainly used to control urinary tract infections (trimethoprim-sulfamethoxazole, nitrofurantoin) did not show seasonal variations. Similar observations on regional differences and seasonal fluctuations have been made in the ESAC study (15) .
Antibiotic consumption in veterinary medicine
The OIE Terrestrial Code has a chapter (currently under revision) which includes recommendations for monitoring the quantities of antimicrobials used in animal husbandry by OIE Member Countries, in order to evaluate usage patterns by antimicrobial class (39) . This guideline is used by France, which gathers information on the volumes of the active ingredients sold by drug companies and attempts to apportion these volumes to the various target species. This method has the same shortcomings as those used by other countries, where the reasons behind trends, such as disease outbreaks and other prevailing conditions, are not addressed.
Grave et al. (21) compared sales of veterinary antibacterial agents from ten European countries, and argued that data generated from surveying the use of veterinary antibacterial agents are essential to identify and quantify risk factors for the development and occurrence of resistance in animals, as well as for their impact on human health. Whilst a number of the national AMR surveillance programmes also report on usage, it is important to understand the limitations of such data. The conclusion from Grave et al. (21) was that there appears to be a wide variation between countries in the use of veterinary antimicrobial agents that cannot be explained by differences in the demographics of animal species. However, even when usage data are compiled, we need to understand that these data do not always explain how the antimicrobials have been used, in what formulation, for what species or why they were chosen; the availability of this information varies throughout the EU. An additional problem with national estimates, where they exist, is the current lack of understanding of the biological relevance of these aggregated data to the antimicrobial resistance data derived from animal, human, food and environmental samples. So, while it is agreed that antimicrobial usage data are important, and indeed essential, to monitor and interpret resistance trends in both animals and people, these data should never be used as definitive proof of a causal association between the two.
Ideally, for antimicrobial usage data to have relevance to resistance-development patterns, these data should be recorded on the farm, along with the indication for treatment, the route of administration, the dose and duration and other relevant data, such as prevailing disease patterns and incidence. Only when such data are provided can information on the use of antimicrobials be used to assess cause and effect with any great accuracy. However, the collection of such data is understood to be a challenge because of the resources it would require.
There is clearly a real need to collect data on antimicrobial use throughout Europe in a consistent manner, to help in interpreting information on resistance monitoring and resistance development. These data could then be used as some of the inputs for science-based risk assessment before considering risk management options. In Europe, data are collected in several EU Member States (the Netherlands, Denmark, Sweden, the UK and France) but there are discrepancies in the type of information that is being collected and reported. It is argued that any system should follow certain basic principles, including the following:
-data should be collected in a reliable, efficient, consistent and verifiable manner, providing confidentiality for pioneer and generic products -cumulative data should be presented in a format that makes them scientifically useful to researchers, risk assessors and other stakeholders, yet balances the level of detail with the resources necessary to obtain it -data should be collected together with contextual data on animal production, food production, disease prevalence and other external factors that may influence antimicrobial use.
In addition, risk managers should consult with stakeholders in interpreting the data.
The situation in Europe is improving, as a result of the European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) project, launched by EMA in September 2009. This initiative followed a request from the European Commission to develop a harmonised system to collect and report data from Member States on the use of antimicrobial agents in animals. To gain experience in analysing and reporting such data at the Community level, the EMA has published a report in which it took existing information on the sales of veterinary antimicrobial agents from those countries with established surveillance programmes, categorised it and reported it in a harmonised manner (18 One major finding of the report was the substantial difference in prescribing patterns of veterinary antimicrobial agents among countries. In general, the authors suggested that these variations may be due to differences in:
-the availability of veterinary antibacterial products on the market from country to country -prices -risk-management measures -the prescribing behaviour of veterinarians -animal production systems (e.g. veal calves as opposed to beef cattle on pasture)
-the general infectious disease situation in each country.
The report also acknowledged that antimicrobial class repartition and prescribing patterns vary among species, and so variations in animal demographics between countries may partially explain the observed correlations. However, other factors also need to be considered. The authors recognised that, since the data presented in the report were aggregated per antimicrobial class, they did not allow for more in-depth analysis, yet to identify the factors underlying the observed differences, more detailed data are needed. For example, as some agents are administered in much higher dosages than others (e.g. tetracyclines versus cephalosporins), we need to continue to refine our tools for analysing data on the sales of antimicrobial agents. The ESVAC project is a welcome move forward.
Clearly, any collection system needs to be robust, simple and practical, based on sales of active ingredient by formulation for the various classes of antimicrobials and apportioning animal species to the sales. For example, the concept of the 'average daily dose' has the advantages of:
-more accurately predicting the exposure of animals of different weights to antibiotics -being more easily used for comparison over time between countries -addressing the differences in potency between antimicrobials of the same class.
Such indicators -and indeed there may be others that will be proposed as a result of the ESVAC initiative -should be developed as appropriate.
Many authorities have recognised that information presented as aggregate data collected nationally has shortfalls. This may be perfectly acceptable in small countries like the Netherlands and Denmark, where prevailing conditions may not vary that widely across their territories. However, in larger countries, such as France and Germany, conditions may vary greatly from region to region, as may disease incidence. Reporting aggregate data therefore makes it difficult to interpret the information if there have been disease outbreaks in certain species, such as pigs or poultry, in certain parts of the country, but these are unknown to the compilers of the report.
In conclusion, the authors would like to emphasise the need to collect data on antimicrobial use throughout Europe in a consistent manner, to assist in interpreting information on resistance monitoring and resistance development. Such data could then be used as partial inputs for science-based risk assessments before considering risk management options. 
Resumen
En varios países del mundo se han llevado a cabo estudios de vigilancia y seguimiento de las resistencias a agentes antimicrobianos en las bacterias de origen humano o animal y del consumo de esos agentes por parte de personas y animales. En el terreno de la veterinaria, en particular, se han instituido programas para estudiar específicamente bacterias de importancia zoonótica, transmitidas por los alimentos y/o de interés veterinario. Cada año, como parte del proyecto de vigilancia europea del consumo de antimicrobianos [European Surveillance of Antimicrobial Consumption], se resume y evalúa el consumo de antimicrobianos por los pacientes de la asistencia ambulatoria u hospitalaria de muchos países europeos. En cambio, solo unos pocos países disponen de datos sobre el consumo de antimicrobianos en la medicina veterinaria, y el tipo de información obtenida es dispar. Para responder a este problema, en septiembre de 2009 la Agencia Europea del Medicamento puso en marcha el proyecto de vigilancia europea del consumo de antimicrobianos de uso veterinario [European Surveillance of Veterinary Antimicrobial Consumption] y acaba de publicar su primer informe. La comparación entre los estudios de vigilancia y seguimiento de la resistencia a los antimicrobianos y el consumo de estos agentes en el ser humano y en los animales pone de manifiesto la necesidad de avanzar hacia un mayor grado de armonización.
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